Titoli: Laurea in Medicina e Chirurgia in data 13/03/1990 presso l'Università di Genova



Download 19.53 Kb.
Date05.08.2017
Size19.53 Kb.
#26255
Curriculum vitae

Dott. Daniele Mattei


Nato il 23/08/1963 a Genova
Iscritto all'Albo dei Medici Chirurghi di Cuneo
Titoli:

Laurea in Medicina e Chirurgia in data 13/03/1990 presso l'Università di Genova

Abiltazione in data 30/05/1990 presso l'Università di Genova

Specializzazione in Ematologia Generale in data 06/07/1993 presso l'Università di Genova

Specializzazione in Medicina Interna in data 08/11/1999 presso l'Università di Cagliari

Ha prestato servizio in qualità di Ufficiale Medico di Complemento presso la Scuola D’Applicazione di Torino dall’aprile 1991 al marzo 1992, dal 31/12/1993 all’08/1/1997 Assistente Medico di Ematologia presso la Divisione di Ematologia dell’Ospedale Oncologico Armando Businco di Cagliari, dal 09/01/1997 sino alla data odierna in servizio presso l’UOA di Ematologia dell’ASO S.Croce e Carle di Cuneo in qualità di Dirigente Medico di I° livello di Ematologia. Referente per il GIMEMA ed il NILG per la terapia delle leucemie acute. Membro dell’European Group for Blood and Marrow Transplantation, dell’American Society of Hematology.


Il sottoscritto è autore/coautore delle seguenti pubblicazioni :
1) Santini G, Nati S, Spriano M, Gallamini A, Pierluigi D, Congiu AM, Truini M, Rubagotti A, Chisesi T, Vimercati R, Rossi E, Sertoli MR, Mattei D, Marino G, Gobbi M. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non Hodgkin’s lymphoma. Haematologica 2001; 86:282-6.
2) Mattei D, Saglio G, Gottardi E, Gallamini A, Mordini N, Bacigalupo A. Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. Haematologica 2001; 86:545-6.
3) Mattei D, Mordini N, Lo Nigro C, Ghirardo D, Ferrua MT, Osenda M, Gallamini A, Bacigalupo A, Viscoli C.

Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation. Bone Marrow Transplant 2002;30:967-70.


4) Mattei D, Mordini N, Lo Nigro C, Gallamini A, Osenda M, Pugno F, Viscoli C. Successful treatment of

Acremonium fungemia with voriconazole. Mycoses 2003;46:511-4.


5) Pagano L, Pulsoni A, Tosti ME, Caramatti C, Cerri R, Falcucci P, Fazi P, Fianchi L, Martino B, Mattei D,

Offidani M, Pacilli L, Pogliani EM, Rotoli B, Specchia G, Visani G, Vignetti M, Voso MT, Leone G, Mandelli F.

Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials. Leukemia. 2004;18:651-3.
6) Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-9.
7) Mattei D, Rapezzi D, Mordini N, Cuda F, Lo Nigro C, Musso M, Arnelli A, Cagnassi S, Gallamini A.

False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillinclavulanic acid treatment. J Clin Microbiol 2004;42:5362-3.


8) Mattei D, Mordini N, Rapezzi D et al. Authors’ reply. J Clin Microbiol 2005;43:2548-9.
9) Mattei D, Mordini N, Vigna Taglianti R, Bruno B, Rapezzi D, Gallamini A. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse. Haematologica/The Hematology Journal 2005; 90:871-2.
10) Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Iannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G NK-T cell lymphomas 'nasal type': an italian multicentric retrospective survey.Ann Onc 2006;17:794-800.
11) Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, Bonifazi F, Petrucci MT, Milone G, Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, Corradini P; Gruppo Italiano Trapianti di Midollo. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic stem cell transplantation. Haematologica/The Hematology Journal 2006;91:837-9.
12) Pagano L, Caira M, Candoni M, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM -2004 study. Hematologica 2006;91:1068-1075.
13) Bruno B, Patriarca F, Sorasio R et al. Bortezomib with or without dexamethasone in relapsed multiple

myeloma following allogeneic hematopoietic stem cell transplantation. Haematologica/The Hematology Journal 2006;91:837-9.


14) Giaccone L, Sorasio R, Patriarca F, Mattei D, Montefusco V, Peccatori J, Carnevale-Schianca F, Petrucci MT, Milone G, Guidi S, Rotta M, Fanin R, Corradini P, Boccadoro M, Bruno B. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment. Biol Blood Marrow Transplant 2007;13:497-479
15) Mattei D, Bassan R, Mordini N, Rapezzi D, Rambaldi A, Strola G, Peretti C, Del Grosso F, Ferraris AM,

Castellino C, Gallamini A. Expansion of B cell precursors after unrelated cord blood transplantation for an adult patient. Bone Marrow Transplant 2007; 40:283-285.


16) Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, Aloisi T, Irrera G, Bonini A, Picardi M,

Caramatti C, Invernizzi R, Mattei D, Melillo L, de Waure C, Reddiconto G, Fianchi L, Valentini CG, Girmenia C, Leone G, Aversa F. Fungal infections in recipients of hematopoietic stem cell transplants: results of SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45:11.


17) Caira M, Girmenia C, Fadda RM, Mitra ME, Picardi M, Van Lint MT, Nosari A, Candoni A, Bonini A, Mattei D, de Waure C, Fianchi L, Valentini CG, Aversa F, Leone G, Pagano L. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur J Haematol. 2008; 81:242-3.
18) Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A, Casini M,Parma M, Bavaro P, Onida F, Busca A, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo A, Corradini P, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood.

2009;113:3375-82.


19) Latagliata R, Breccia M, Fazi P, Iacobelli S, Martinelli G, Di Raimondo F, Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A, Amadori S, Caramatti C, Falzetti F, Candoni A, Mattei D, Morselli M, Alimena G, Vignetti M, Baccarani M, Mandelli F. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of

the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol. 2008;143:681-9.


20) Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukaemia (ALL). Blood. 2009;113:4153-62.

21) Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversibile dasatinib-induced pulmonary

arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43:967-8.
22) Mattei D, Sorasio R, Guarnieri A, Marazzi F, Formica M, Fortunato M, Mordini N, Rapezzi D, Gallamini A.

Long-term results of rituximab treatment for membranous nephropathy after allogeneic hematopoietic SCT: a

case report. Bone Marrow Transplant. 2009 Sep 28. [Epub ahead of print] PubMed PMID: 19784075.

23) Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic

leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010 Aug 1;28(22):3644-52.
24) Cortelazzo S, Intermesoli T, Oldani E, Ciceri F, Rossi G, Pogliani EM, Mattei D, Romani C, Cortelezzi A, Borlenghi E, Corti C, Peruta B, Spinelli O, Rambaldi A, Bassan R. Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. Ann Hematol. 2012 Jan;91(1):73-82.
25) Mannelli F, Gianfaldoni G, Intermesoli T, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Pogliani EM, Fumagalli M, Angelucci E, Romani C, Ciceri F, Corti C, Scattolin A, Cortelezzi A, Mattei D, Audisio E, Spinelli O, Oldani E, Bosi A, Rambaldi A, Bassan R. CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from

the molecular study of minimal residual disease. Haematologica. 2012 Apr;97(4):568-71.


26) Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, Pagani C, Angelucci E, Terruzzi E, Levis A, Cassibba V, Mattei D, Gianfaldoni G, Scattolin AM, Di Bona E, Oldani E, Parolini M, Gökbuget N, Bassan R. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013 Nov;98(11):1718-25.
27) Sorasio R, Bonferroni M, Grasso M, Strola G, Rapezzi D, Marenchino D, Di Marco

C, Castellino C, Mattei D, Mordini N, Fiore F, Celeghini I, Borra A, Ghiglia A, Gallamini A. Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience. Biol Blood Marrow Transplant. 2014 May;20(5):717-23.


28) Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Borlenghi E, Pogliani EM, Di Bona E, Cassibba V, Scattolin AM, Romani C, Ciceri F, Cortelezzi A, Gianfaldoni G, Mattei D, Audisio E, Rambaldi A. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem celltransplantation outcome in adult Philadelphia-negative acute lymphoblasticleukemia. Blood Cancer J. 2014 Jul 11;4:e225.

29) Bassan R, Masciulli A, Intermesoli T, Audisio E, Rossi G, Pogliani EM, Cassibba V, Mattei D, Romani C, Cortelezzi A, Corti C, Scattolin AM, Spinelli O, Tosi M, Parolini M, Marmont F, Borlenghi E, Fumagalli M, Cortelazzo S, Gallamini A, Marfisi RM, Oldani E, and Rambaldi A. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. Haematologica. 2015; 100:xxx doi:10.3324/haematol.2014.123273

Download 19.53 Kb.

Share with your friends:




The database is protected by copyright ©ininet.org 2024
send message

    Main page